Kyra Doumlele
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kyra Doumlele has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Arushi Kapoor
University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America
1 shared publication Carol Chan
Case Western Reserve University School of Medicine, Cleveland, United States of America
1 shared publicationCyndi Wright
Epilepsy Foundation Landover MD United States
1 shared publication- Dale C. Hesdorffer
Department of Epidemiology, G. H. Sergievsky Center Columbia University New York New York USA
1 shared publication - Daniel J. Friedman
Division of Cardiology, Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
1 shared publication David Fowler
Office of the Chief Medical Examiner Baltimore MD United States
1 shared publication
Latest Publications
- 5 September 2025
- Published by Springer Nature in Current Geriatrics Reports
- Vol. 14 (1) , 1-14
Treatment Approaches To Anxiety and Depression in Parkinson’s Disease
- 5 September 2025
- Published by Springer Nature in Current Geriatrics Reports
- Vol. 14 (1) , 1-14
Treatment Approaches To Anxiety and Depression in Parkinson’s Disease
- Open Access
- 21 June 2024
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 52 (6)
Is there evidence for using ketamine among individuals with dementia?
The aim of this short narrative review was to evaluate the existing literature regarding the clinical use of ketamine among individuals with dementia, especially those with behavioral disturbances. PubMed, Cochrane, and Ovid (Embase, APA PsycINFO, and MEDLINE) databases were searched for abstracts using the search terms “ketamine” AND “dementia.” Only articles describing the use of ketamine in individuals with dementia were included. Articles that did not include individuals with dementia, did not use ketamine, were published in a non-English language, primarily described animal studies, or were reviews were excluded. Three case reports met the inclusion criteria. One described the use of subcutaneous ketamine for depression, one described the use of intramuscular ketamine for acute agitation, and one described the use of S-ketamine as anesthesia during electroconvulsive therapy for depression and catatonia. No significant adverse effects were reported in any of the cases. Although the use of ketamine in the treatment of depression and agitation associated with dementia has potential, the current evidence remains limited. High-quality prospective studies are needed to confirm the observations of these case reports before ketamine can be used to treat behavioral disturbances in individuals with dementia.
- 21 June 2024
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 52 (6)
Open AccessIs there evidence for using ketamine among individuals with dementia?
The aim of this short narrative review was to evaluate the existing literature regarding the clinical use of ketamine among individuals with dementia, especially those with behavioral disturbances. PubMed, Cochrane, and Ovid (Embase, APA PsycINFO, and MEDLINE) databases were searched for abstracts using the search terms “ketamine” AND “dementia.” Only articles describing the use of ketamine in individuals with dementia were included. Articles that did not include individuals with dementia, did not use ketamine, were published in a non-English language, primarily described animal studies, or were reviews were excluded. Three case reports met the inclusion criteria. One described the use of subcutaneous ketamine for depression, one described the use of intramuscular ketamine for acute agitation, and one described the use of S-ketamine as anesthesia during electroconvulsive therapy for depression and catatonia. No significant adverse effects were reported in any of the cases. Although the use of ketamine in the treatment of depression and agitation associated with dementia has potential, the current evidence remains limited. High-quality prospective studies are needed to confirm the observations of these case reports before ketamine can be used to treat behavioral disturbances in individuals with dementia.
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Experiences with Premorbid SUDEP Discussion among Participants in the North American SUDEP Registry (NASR) (P6.361)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Experiences with Premorbid SUDEP Discussion among Participants in the North American SUDEP Registry (NASR) (P6.361)